WKWolfram Klapper

Wolfram Klapper

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wolfram Klapper has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • A Sotnikova

    Department of Haematopathology and Lymph Node Registry Kiel, Schleswig‐Holstein University Hospitals, Campus Kiel, Niemannsweg 11, 24105 Kiel, Germany

    1 shared publication
  • Anna Sotnikova

    Department of Pathology, Haematopathology and Lymph Node Registry, Schleswig‐Holstein University Hospitals, Kiel, Germany

    1 shared publication
  • Eva Hoster

    Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany

    1 shared publication
  • Gaixiang Xu

    Department of Pathology, Haematopathology and Lymph Node Registry, Schleswig‐Holstein University Hospitals, Kiel, Germany

    1 shared publication
  • Hans-Juergen Heidebrecht

    Institute for Immunology, University Hospital Schleswig-Holstein Campus Kiel, Arnold-Heller-Str. 3, Bldg 17, Kiel, 24105, Germany

    1 shared publication
  • J Greeve

    Department of Internal Medicine, Inselspital‐University Hospital Bern, 3010 Bern, Switzerland

    1 shared publication

Latest Publications

  • Follicular dendritic cells in follicular lymphoma and types of non‐Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome

    by Mi Kyung Jin, Eva Hoster, Martin Dreyling, Michael Unterhalt, Wolfgang Hiddemann, Wolfram Klapper

    Jin M K, Hoster E, Dreyling M, Unterhalt M, Hiddemann W & Klapper W (2011) Histopathology 58, 586–592 Follicular dendritic cells in follicular lymphoma and types of non‐Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcomeAims:  Follicular dendritic cells (FDC) are specialized antigen‐presenting cells found exclusively in the germinal centre (GC), which can be detected in B cell non‐Hodgkin lymphomas (NHL) as reactive bystander cells. Recently, gene expression profiling has revealed that FDC networks might be associated with clinical outcome in follicular lymphoma. The aim was to characterize FDC in NHL and to evaluate a possible association with outcome in follicular lymphoma.Methods and results:  The extent and immunophenotype of FDC was determined semi‐quantitatively in reactive GC and NHL (follicular lymphoma, angioimmunoblastic T cell lymphoma, mantle cell lymphoma) using fluorescence double staining and digital image analysis. In all NHL tested CD23 and CD35 and CD54 were expressed at relatively low levels on FDC, comparable to FDC found in the dark zone of the GC. However, the extent of FDC networks did not correlate with the clinical outcome of 102 patients with follicular lymphomas treated within a prospectively randomized trial.Conclusions:  FDC found in different types of NHL show quantitatively reduced expression of several proteins, suggesting that there are functional differences between FDC in normal GC and NHL. The extent of the FDC networks in follicular lymphoma is not useful as a prognostic marker.


  • Regulation of repp86 stability by human Siah2

    by Monika Szczepanowski, Sabine Adam-Klages, Marie-Luise Kruse, Marc Pollmann, Wolfram Klapper, Reza Parwaresch, Hans-Juergen Heidebrecht


  • Loss of expression of LyGDI (ARHGDIB), a rho GDP‐dissociation inhibitor, in Hodgkin lymphoma*

    by Liya Ma, Gaixiang Xu, Anna Sotnikova, Monika Szczepanowski, Maciej Giefing, Kristina Krause, Matthias Krams, Reiner Siebert, Jie Jin, Wolfram Klapper

    Summary: The guanosine triphosphatase (GTPase) inhibitor LyGDI (ARHGDIB, Ly/D4‐GDI, RhoGDIb or RhoGDI 2) is abundantly expressed in haematopoetic cells and possibly plays a role in the onset of apoptosis. Gene expression profiling of Hodgkin cell lines revealed that LyGDI expression was downregulated in these cell lines. The present study evaluated the expression of LyGDI in Hodgkin cells in vivo and studied the function of LyGDI in Hodgkin cell lines in vitro. Our results showed that virtually all Hodgkin and Reed‐Sternberg cells in classical Hodgkin lymphoma lacked LyGDI protein expression. On the other hand, almost all non‐Hodgkin lymphomas, except for anaplastic large cell lymphomas, expressed LyGDI protein. Transfection of the classical Hodgkin cell line L428 with a vector containing full‐length LyGDI‐induced apoptosis in a subset of cells. However, the majority of Hodgkin cells with transgenic expression of LyGDI escaped apoptosis. Our data show that lack of LyGDI expression is a frequent feature of cHL but that it is not of vital importance for the growth and survival of these cells.


  • Immunoglobulin class‐switch recombination occurs in mantle cell lymphomas

    by W Klapper, M Szczepanowski, K Heidorn, M Müschen, S Liedtke, A Sotnikova, Ns Andersen, J Greeve, R Parwaresch

    Mantle cell lymphoma (MCL) is an IgM‐expressing B cell lymphoma that originates from naive B cells and responds poorly to chemotherapy. We show here that several MCLs harbour isotype‐switched subclones. Similar to the situation in normal B cells, in vitro stimulation of MCL cell lines with CD40 ligand (CD40L) and interleukin‐4 induced expression of activation‐induced cytidine deaminase (AID) and germline transcription at the immunoglobulin heavy chain gene locus. Additionally, the occurrence of switch‐circle transcripts and mature IgG transcripts after stimulation indicated ongoing class‐switch recombination in mantle cell lymphoma cell lines. Furthermore, stimulation of primary MCL cells in vitro induced expression of class‐switched IgG mRNA in the tumour cells. Our data indicate that mantle cell lymphomas have retained the ability to undergo class‐switch recombination if appropriate stimuli, such as the CD40 ligand, are provided. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.